Novo Nordisk A/S

• Wall Street banked on a flurry of deals under Trump in 2025. It wasn't that simple - Dealmakers expected a flood of M&A to take place in 2025 following the election of President Trump. The number of transactions didn't live up to the hype.
• This is how exposed European Big Pharma is to the U.S. - U.S. pricing has been the bigegts issue of the year for drugmakers heavily exposed to the U.S. market.
• Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial   - The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. 
• Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.